Q4 2024 argenx SE Earnings Call Transcript
Key Points
- argenx SE (ARGNF) expanded its reach to over 10,000 patients globally across three approved indications in 2024.
- The company achieved several key clinical milestones, including advancing efgartigimod into larger registration studies and nominating four new pipeline molecules.
- VYVGART has significantly impacted the gMG treatment landscape, with strong early adoption in CIDP patients.
- argenx SE (ARGNF) expects 2025 to be its first profitable year, reflecting commercial success and disciplined innovation scaling.
- The company maintains a strong financial position with a cash balance of $3.4 billion at year-end 2024.
- The company faces increased gross to net dynamics due to self-administration, which may impact financials.
- Operating expenses increased by $83 million in Q4 2024, primarily due to a $61 million rise in R&D expenses.
- argenx SE (ARGNF) reported an operating loss of $22 million for the full year 2024.
- Exchange losses of $55 million were incurred in Q4 2024, mainly related to unrealized FX on non-US denominated cash balances.
- The company anticipates a 25% increase in combined R&D and SG&A expenses for 2025, reflecting a commitment to pipeline growth.
Good morning. My name is Rob, and I will be your conference operator today. I would like to welcome everyone to the call. (Operator Instructions)
Thank you. I'd now like to introduce Beth DelGiacco, Vice President, Corporate Communications and Investor Relations. You may begin your conference.
&
Thank you. A press release was issued earlier today with our fourth quarter and full year 2024 financial results and business update. This can be found on our website along with the presentation for today's webcast.
Before we begin, on Slide 2, I'd like to remind you that forward-looking statements may be presented during this call. This may include statements about our future expectations, clinical development, regulatory time lines, the potential success of our product candidates, financial projections and upcoming milestones.
Actual results may differ materially from those indicated by these statements. Argenx is not under any obligation to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
